News and Trends 24 Oct 2019
German Alzheimer’s Drug Backed with €43M After Biogen’s Surprise Turnaround
…an upcoming European phase IIb trial of Vivoryon’s lead candidate small molecule drug in around 250 patients with Alzheimer’s disease, the most common form of dementia. Results are expected in…